Boston close to solving coronary stent problems
This article was originally published in Clinica
Executive Summary
Boston Scientific is predicting that its problems with the Nir-on-Ranger with SOX coronary stent may soon be over, as is trying to get the product back on the US market within four months. The company also forecast that it would increase revenue by a third this year, although it is to cut around 2,000 jobs as part of the Schneider Worldwide amalgamation.